Publication | Open Access

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

OncologyStandard ChemotherapyRandomised Phase 3PathologyBronchial NeoplasmEuropean PatientsCancer TreatmentMedicineRadiation OncologyLung CancerMolecular Oncology